- Home
- CGBD vs REPL Comparison
CGBD vs REPL Comparison
Compare CGBD & REPL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CGBD
- REPL
- Stock Information
- Founded
- CGBD 2012
- REPL 2015
- Country
- CGBD United States
- REPL United States
- Employees
- CGBD N/A
- REPL N/A
- Industry
- CGBD Finance: Consumer Services
- REPL Biotechnology: Pharmaceutical Preparations
- Sector
- CGBD Finance
- REPL Health Care
- Exchange
- CGBD Nasdaq
- REPL Nasdaq
- Market Cap
- CGBD 909.7M
- REPL 780.3M
- IPO Year
- CGBD 2017
- REPL 2018
- Fundamental
- Price
- CGBD $18.35
- REPL $11.85
- Analyst Decision
- CGBD Hold
- REPL Strong Buy
- Analyst Count
- CGBD 4
- REPL 6
- Target Price
- CGBD $16.25
- REPL $17.50
- AVG Volume (30 Days)
- CGBD 268.8K
- REPL 818.5K
- Earning Date
- CGBD 02-25-2025
- REPL 02-06-2025
- Dividend Yield
- CGBD 7.58%
- REPL N/A
- EPS Growth
- CGBD 29.39
- REPL N/A
- EPS
- CGBD 1.72
- REPL N/A
- Revenue
- CGBD $238,921,000.00
- REPL N/A
- Revenue This Year
- CGBD N/A
- REPL N/A
- Revenue Next Year
- CGBD $4.63
- REPL $300.41
- P/E Ratio
- CGBD $10.64
- REPL N/A
- Revenue Growth
- CGBD 1.68
- REPL N/A
- 52 Week Low
- CGBD $14.76
- REPL $4.92
- 52 Week High
- CGBD $18.74
- REPL $17.00
- Technical
- Relative Strength Index (RSI)
- CGBD 60.10
- REPL 51.79
- Support Level
- CGBD $17.31
- REPL $10.05
- Resistance Level
- CGBD $18.56
- REPL $11.20
- Average True Range (ATR)
- CGBD 0.29
- REPL 0.92
- MACD
- CGBD 0.01
- REPL -0.08
- Stochastic Oscillator
- CGBD 83.20
- REPL 51.97
About CGBD Carlyle Secured Lending Inc.
Carlyle Secured Lending Inc is a specialty finance company that is a closed-end, externally managed, non-diversified management investment company. It focuses on providing directly originated, financing solutions across the capital structure, with a focus on senior secured lending to middle-market companies located in the United States. The company's investment objective is to generate current income and capital appreciation through debt investments in U.S. middle-market companies.
About REPL Replimune Group Inc.
Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. Its pipeline products include RP1, RP2, and RP3.